Dynavox Group ABTDVXF -3.17%89 EBITDA Margin % is 19.05% as of Mar. 2026, which is 4% below its 10-year median of 19.87. GuruFocus rates TDVXF with a GF Score™ of 89/100 and a GF Value™ of $8.94 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Dynavox Group AB ranks better than 75.15% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Dynavox Group AB's EBITDA for the
three
months ended in Mar. 2026 was $12.0 Mil. Dynavox Group AB's Revenue for the
three
months ended in Mar. 2026 was $63.1 Mil. Therefore, Dynavox Group AB's EBITDA margin for the quarter that ended in Mar. 2026 was 19.05%.
Dynavox Group AB (OTCPK:TDVXF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Dynavox Group AB EBITDA Margin % Related Terms
Dynavox Group AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Dynavox Group AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TDVXF vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Dynavox Group AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynavox Group AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Dynavox Group AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Dynavox Group AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynavox Group AB (TDVXF) has a EBITDA Margin % of 19.05% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dynavox Group AB and its competitors. This is near median its historical median of 19.87. Over the past decade, Dynavox Group AB's EBITDA Margin % has ranged from 16.34 to 23.85. According to the industry distribution chart, Dynavox Group AB ranks #202 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 24.8%.
Is Dynavox Group AB's EBITDA Margin % too high?
Dynavox Group AB's current EBITDA Margin % of 19.05% is near median its 10-year median of 19.87. Over the past 10 years, this metric has ranged from a low of 16.34 to a high of 23.85. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Dynavox Group AB's value of 19.05% is 155% above this industry median. Based on the distribution chart, Dynavox Group AB ranks #202 out of 813 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Dynavox Group AB has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dynavox Group AB's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Dynavox Group AB ranks #202 out of 813 companies for EBITDA Margin %. This places Dynavox Group AB in the top 25% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.47. Dynavox Group AB's value of 19.05% is 155% above this benchmark. Historically, Dynavox Group AB's own EBITDA Margin % has ranged from 16.34 to 23.85 over the past decade. While the company's 10-year median is 19.87 vs. the industry median of 7.47, Dynavox Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dynavox Group AB's current EBITDA Margin % of 19.05% is 155% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Dynavox Group AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dynavox Group AB's current EBITDA Margin % is 19.05%, which is near median its own 10-year median of 19.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dynavox Group AB stock overvalued right now?
Based on GuruFocus' analysis, Dynavox Group AB (TDVXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.94, compared to a current price of $6.57 — trading 26.5% below its estimated fair value. The current EBITDA Margin % is 19.05%, which is near median its 10-year median of 19.87 and 155% above the Medical Devices & Instruments industry median of 7.47. Dynavox Group AB's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Dynavox Group AB (TDVXF), the current EBITDA Margin % is 19.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dynavox Group AB (TDVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Dynavox Group AB stock appears to be undervalued.
The current stock price of $6.57 is trading 26.5% below its estimated GF Value™ of $8.94.
GuruFocus considers Dynavox Group AB to be Modestly Undervalued.
Key valuation signals for TDVXF:
EBITDA Margin %: 19.05% (near median its 10-year median of 19.87)
GF Value™: $8.94 vs. price of $6.57 (26.5% below fair value)
Industry Position: 155% above the Medical Devices & Instruments median (#202 of 813)
No single metric tells the full story. See the TDVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dynavox Group AB is engaged in assistive technology for communication. The company's Augmentative and Alternative Communication (AAC) solutions enable people with disabilities such as cerebral palsy, ALS, and spinal cord injury to communicate with a voice of their own, develop literacy skills, and live more independently. The company is a comprehensive SaaS provider with local roots. The company operates in Europe, North America, and Other countries, with the majority of revenue from North America.
89GF Score
Get the complete analysis for TDVXF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TDVXF has been successfully added to your 
